CN117503985A - Medical soft tissue adhesive and preparation method and application thereof - Google Patents
Medical soft tissue adhesive and preparation method and application thereof Download PDFInfo
- Publication number
- CN117503985A CN117503985A CN202311521057.1A CN202311521057A CN117503985A CN 117503985 A CN117503985 A CN 117503985A CN 202311521057 A CN202311521057 A CN 202311521057A CN 117503985 A CN117503985 A CN 117503985A
- Authority
- CN
- China
- Prior art keywords
- soft tissue
- tissue adhesive
- weight
- medical soft
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004872 soft tissue Anatomy 0.000 title claims abstract description 50
- 239000003106 tissue adhesive Substances 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 44
- 230000001070 adhesive effect Effects 0.000 claims abstract description 31
- 239000000853 adhesive Substances 0.000 claims abstract description 29
- 239000003112 inhibitor Substances 0.000 claims abstract description 27
- IJVRPNIWWODHHA-UHFFFAOYSA-N 2-cyanoprop-2-enoic acid Chemical compound OC(=O)C(=C)C#N IJVRPNIWWODHHA-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000004014 plasticizer Substances 0.000 claims abstract description 12
- 239000002562 thickening agent Substances 0.000 claims abstract description 10
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 38
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 32
- 238000002156 mixing Methods 0.000 claims description 16
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims description 12
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 claims description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 6
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 239000001069 triethyl citrate Substances 0.000 claims description 3
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000013769 triethyl citrate Nutrition 0.000 claims description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 2
- JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 claims description 2
- RPQUGMLCZLGZTG-UHFFFAOYSA-N octyl cyanoacrylate Chemical compound CCCCCCCCOC(=O)C(=C)C#N RPQUGMLCZLGZTG-UHFFFAOYSA-N 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 abstract description 13
- 230000000694 effects Effects 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 5
- 206010046996 Varicose vein Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000027185 varicose disease Diseases 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003836 peripheral circulation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- FGBJXOREULPLGL-UHFFFAOYSA-N ethyl cyanoacrylate Chemical compound CCOC(=O)C(=C)C#N FGBJXOREULPLGL-UHFFFAOYSA-N 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/0005—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
Abstract
The invention provides a medical soft tissue adhesive, a preparation method and application thereof, wherein the medical soft tissue adhesive comprises the combination of alpha-cyanoacrylate, plasticizer, thickener, retarder and polymerization inhibitor in specific parts; the specific components are matched with each other, the dosage of each component is limited, and the polymerization inhibitor and the retarder are added to control the polymerization speed of the medical soft tissue adhesive, so that the obtained medical soft tissue adhesive has proper polymerization speed, excellent fluidity and excellent adhesive strength, and is particularly suitable for the adhesion of blood vessels.
Description
The invention claims priority of 2022115794893 patent application (the application date of the prior application is 2022, 12 and 06 days, and the invention name is medical soft tissue adhesive, and a preparation method and application thereof).
Technical Field
The invention belongs to the technical field of adhesives, and particularly relates to a medical soft tissue adhesive, and a preparation method and application thereof.
Background
The medical soft tissue adhesive is an adhesive suitable for bonding skin, organs, nerves, muscles, blood vessels and mucous membranes, and the relatively ideal medical adhesive can be bonded under water and/or tissue fluid, can be bonded rapidly at body temperature, has good biocompatibility with human body, generates larger bonding strength with tissues after curing bonding and has good toughness.
Among them, adhesives suitable for blood vessels are most commonly discussed in terms of the combination of physical and biological properties with respect to the study of surrounding blood vessels, pierre-Olivier Comby et al, and the alpha-cyanoacrylate series of adhesives are suitable for various vascular disease management affecting the peripheral circulation, and when in contact with hydroxyl groups in water or different anions in blood, the ethylene units of the alpha-cyanoacrylate build up, thereby acting as a closure to soft tissues. The cyanoacrylate series adhesive is used for treating varicose veins in peripheral circulation blood vessels, and the varicose veins are mainly caused by venous blood vessel tortuosity and expansion due to blood stasis caused by thinner vein blood vessel walls and long-term habit, and vein valve insufficiency. Compared with the traditional operation and action modes of radio frequency, laser and stripping operation for treating varicose veins, the alpha-cyanoacrylate series adhesive can reduce operation time and pain after operation.
In the chemical mechanism of alpha-cyanoacrylate bonding, the longer the hydrocarbon in the chemical structure is, the slower the polymerization rate is, the less heat is released during the polymerization, and the less tissue toxicity is. In combination with the closing requirement of peripheral blood vessels, the selection of the corresponding alpha-cyanoacrylate series adhesive needs to be balanced and selected in terms of polymerization speed, fluidity and the like, the excessively fast polymerization of the adhesive can affect the effect that the whole-course blood vessel closing cannot be achieved in operation, the excessively slow polymerization can lengthen the operation time and operation uncertainty, and the excessively fast fluidity of the adhesive can lead the adhesive to flow out of the blood vessels with non-target actions, so the adhesive needs to balance the polymerization speed, fluidity, adhesive effect and the like.
In order to achieve the effect of the adhesive, the preparation process generally needs to add the rest components on the basis of the alpha-cyanoacrylate series, and the preparation environment conditions need to be controlled to accelerate the process and avoid unexpected reactions due to the difference of the activity degree of the main components and/or the added components. However, the polymerization rate provided by the invention is relatively high, which is disadvantageous for handling, and the adhesive strength of the vascular closure composition is yet to be improved.
Therefore, developing a medical soft tissue adhesive with proper polymerization speed, proper flow speed and high adhesive strength is a technical problem which is urgently needed to be solved in the field.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a medical soft tissue adhesive, a preparation method and application thereof, wherein the medical soft tissue adhesive has proper polymerization speed and excellent fluidity by adding a retarder and a polymerization inhibitor in specific parts, and has excellent adhesive property after film formation.
To achieve the purpose, the invention adopts the following technical scheme:
in a first aspect, the invention provides a medical soft tissue adhesive, which comprises the following components in parts by weight:
wherein the content of the alpha-cyanoacrylate may be 72 parts by weight, 74 parts by weight, 76 parts by weight, 78 parts by weight, 80 parts by weight, 82 parts by weight, 84 parts by weight, 86 parts by weight, 88 parts by weight, or the like.
The plasticizer may be 6 parts by weight, 7 parts by weight, 8 parts by weight, 9 parts by weight, 10 parts by weight, 11 parts by weight, 12 parts by weight, 13 parts by weight, 14 parts by weight, 15 parts by weight, 16 parts by weight, 17 parts by weight, 18 parts by weight, 19 parts by weight, or the like.
The thickener may be 3 parts by weight, 4 parts by weight, 5 parts by weight, 6 parts by weight, 7 parts by weight, 8 parts by weight, 9 parts by weight, 10 parts by weight, or the like.
The retarder may be 0.2 parts by weight, 0.4 parts by weight, 0.6 parts by weight, 0.8 parts by weight, 1 parts by weight, 1.2 parts by weight, 1.4 parts by weight, 1.6 parts by weight, 1.8 parts by weight, 2 parts by weight, 2.2 parts by weight, 2.4 parts by weight, 2.6 parts by weight, or 2.8 parts by weight, etc.
The polymerization inhibitor may be 0.2 parts by weight, 0.4 parts by weight, 0.6 parts by weight, 0.8 parts by weight, 1 part by weight, 1.2 parts by weight, 1.4 parts by weight, 1.6 parts by weight, 1.8 parts by weight, or the like.
The medical soft tissue adhesive provided by the invention comprises the combination of the alpha-cyanoacrylate, the plasticizer, the thickener, the retarder and the polymerization inhibitor in specific parts, the components are matched, the dosage of each component is limited, and the polymerization speed of the medical soft tissue adhesive is controlled by adding the polymerization inhibitor and the retarder to match, so that the obtained medical soft tissue adhesive has proper polymerization speed, excellent fluidity and excellent bonding strength, and is particularly suitable for bonding blood vessels.
Preferably, the α -cyanoacrylate comprises α -n-butyl cyanoacrylate and/or α -n-octyl cyanoacrylate.
Preferably, the plasticizer comprises triethyl citrate and/or tributyl citrate.
Preferably, the thickener comprises cellulose acetate butyrate.
Preferably, the retarder comprises any one or a combination of at least two of rosin, salicylic acid or phosphoric acid.
Preferably, the polymerization inhibitor comprises any one or a combination of at least two of hydroquinone, benzoquinone or sulfur dioxide, and more preferably, the combination of hydroquinone and sulfur dioxide.
As a preferable technical scheme of the invention, in order to obtain medical soft tissue adhesive with more excellent comprehensive performance, the advantage of adopting hydroquinone and sulfur dioxide to match as polymerization inhibitor is that the alpha-cyanoacrylate can be prevented from being polymerized too quickly and generating a large amount of polymerization heat under the action of anions more rapidly and effectively.
Preferably, the mass ratio of retarder to polymerization inhibitor is (2-4): 1, e.g., 2.1:1, 2.2:1, 2.3:1, 2.4:1, 2.5:1, 2.6:1, 2.7:1, 2.8:1, 2.9:1, 3.0:1, 3.1:1, 3.2:1, 3.3:1, 3.4:1, 3.5:1, 3.6:1, 3.7:1, 3.8:1, or 3.9:1, etc.).
As a preferable technical scheme of the invention, the mass ratio of the retarder to the polymerization inhibitor is (2-4): 1, so that the polymerization speed of the adhesive can be better controlled, and the adhesive performance of the adhesive after film formation is better.
In a second aspect, the present invention provides a method for preparing the medical soft tissue adhesive according to the first aspect, the method comprising: mixing alpha-cyanoacrylate, plasticizer, thickener, retarder and polymerization inhibitor to obtain the medical soft tissue adhesive.
Preferably, the preparation method specifically comprises the following steps: mixing a retarder, a solid polymerization inhibitor and a plasticizer, adding a thickener, and finally adding a gaseous polymerization inhibitor and alpha-cyanoacrylate for mixing to obtain the medical soft tissue adhesive.
As a preferred technical scheme of the invention, the method for limiting the feeding sequence has the advantages of simple operation process and capability of forming a slow polymerization state and a polymerization inhibition state as soon as possible in the preparation process so as to achieve the expected effect of the adhesive.
Preferably, the retarder, the solid polymerization inhibitor and the plasticizer are mixed for a mixing time of 5 to 30min, for example, 7min, 9min, 11min, 13min, 15min, 17min, 19min, 21min, 23min, 25min, 27min or 29min, etc.
Preferably, the mixing time for mixing the gaseous polymerization inhibitor and the α -cyanoacrylate is 1 to 48 hours, for example, 5 hours, 10 hours, 15 hours, 20 hours, 25 hours, 30 hours, 35 hours, 40 hours, 45 hours, or the like.
In a third aspect, the present invention provides a use of a medical soft tissue adhesive vena cava adhesive according to the first aspect.
Compared with the prior art, the invention has the following beneficial effects:
the medical soft tissue adhesive provided by the invention comprises the combination of alpha-cyanoacrylate, plasticizer, thickener, retarder and polymerization inhibitor in specific parts; the specific components are matched with each other, the dosage of each component is limited, and the polymerization inhibitor and the retarder are added to control the viscosity of the medical soft tissue adhesive to be 550-750 cp, the lap-shear tensile strength to be 0.05-0.09 MPa, the vascular adhesion time to be 25-50 s, the flow time to be 7-8 s, the vascular adhesion film forming effect to be A or B grade, and the adhesive is particularly suitable for adhesion of blood vessels.
Detailed Description
The technical scheme of the invention is further described by the following specific embodiments. It will be apparent to those skilled in the art that the examples are merely to aid in understanding the invention and are not to be construed as a specific limitation thereof.
Example 1
The medical soft tissue adhesive comprises the following components in parts by weight:
| alpha-cyanoacrylate | 80 parts by weight |
| Citric acid triethyl ester | 12 parts by weight |
| Cellulose acetate butyrate | 6 parts by weight |
| Rosin | 1.5 parts by weight |
| Hydroquinone (HQ) | 0.25 weightParts by weight |
| Sulfur dioxide | 0.25 part by weight |
The preparation method comprises the following steps:
(1) Adding rosin and hydroquinone into a clean and dry 250mL reaction kettle, adding triethyl citrate, mixing for about 10min, adding cellulose acetate butyrate, mixing uniformly, sealing the reaction kettle, extracting gas to form negative pressure, adding sulfur dioxide and alpha-cyanoacrylate, mixing until the solid is completely dissolved, packaging, and sterilizing to obtain the medical soft tissue adhesive.
Example 2
The medical soft tissue adhesive comprises the following components in parts by weight:
| alpha-cyanoacrylate | 70 parts by weight |
| Citric acid triethyl ester | 20 parts by weight |
| Cellulose acetate butyrate | 6 parts by weight |
| Rosin | 3 parts by weight |
| Hydroquinone (HQ) | 0.5 part by weight |
| Sulfur dioxide | 0.5 part by weight |
The preparation method is the same as in example 1.
Example 3
The medical soft tissue adhesive comprises the following components in parts by weight:
| alpha-cyanoacrylate | 85 parts by weight |
| Citric acid triethyl ester | 5 parts by weight |
| Cellulose acetate butyrate | 6 parts by weight |
| Rosin | 3 parts by weight |
| Hydroquinone (HQ) | 0.5 part by weight |
| Sulfur dioxide | 0.5 part by weight |
The preparation method is the same as in example 1.
Example 4
A medical soft tissue adhesive is different from example 1 only in that phosphoric acid is used for replacing rosin, and other components, amounts and preparation methods are the same as those of example 1.
Example 5
A medical soft tissue adhesive differs from example 1 only in that sulfur dioxide is not added, hydroquinone is added in an amount of 0.5 parts by weight, and other components, amounts and preparation methods are the same as in example 1.
Example 6
A medical soft tissue adhesive is different from example 1 only in that hydroquinone is not added, the addition amount of sulfur dioxide is 0.5 weight part, and other components, amounts and preparation methods are the same as in example 1.
Example 7
A medical soft tissue adhesive is different from example 1 only in that the addition amount of rosin is 1.8 parts by weight, the addition amount of hydroquinone is 0.1 part by weight, the addition amount of sulfur dioxide is 0.1 part by weight, and other components, amounts and preparation methods are the same as in example 1.
Example 8
A medical soft tissue adhesive is different from example 1 in that rosin is added in an amount of 1 part by weight, hydroquinone is added in an amount of 0.5 part by weight, sulfur dioxide is added in an amount of 0.5 part by weight, and other components, amounts and preparation methods are the same as in example 1.
Comparative example 1
A medical soft tissue adhesive is different from example 1 only in that rosin is not added, the addition amount of hydroquinone is 1 part by weight, the addition amount of sulfur dioxide is 1 part by weight, and other components, amounts and preparation methods are the same as in example 1.
Comparative example 2
A medical soft tissue adhesive is different from example 1 only in that hydroquinone and sulfur dioxide are not added, the addition amount of rosin is 2 parts by weight, and other components, amounts and preparation methods are the same as in example 1.
Comparative example 3
A medical soft tissue adhesive differing from example 1 only in that rosin was added in an amount of 3.5 parts by weight, and other components, amounts and preparation methods were the same as in example 1.
Comparative example 4
A medical soft tissue adhesive differs from example 1 only in that hydroquinone is added in an amount of 1.25 parts by weight, sulfur dioxide is added in an amount of 1.25 parts by weight, and other components, amounts and preparation methods are the same as in example 1.
Performance test:
(1) Viscosity: testing according to the method provided by the single cylinder rotational viscometer method for measuring viscosity of GB/T2794-2013 adhesive;
(2) Lap-shear tensile strength: according to YY/T0729.1-2009 tissue adhesive adhesion test method part 1: testing the method provided by lap-shear tensile load strength;
(3) Vascular adhesion time: testing by a method of HG/T2492-2018 alpha-ethyl cyanoacrylate instant adhesive;
(4) Flow properties: testing the flow time of 2mL of sample in a 10mL penicillin bottle;
(5) Vascular adhesion film-forming effect: uniformly coating the adhesive on the surface of a blood vessel, tearing after pressing for 20-30 s, visually observing the blood vessel to form a film, wherein the film is obviously formed according to the grade A, slightly formed according to the grade B and uncured according to the grade C.
The medical soft tissue adhesive provided in examples 1 to 8 and comparative examples 1 to 4 were tested according to the above test methods, and the test results are shown in table 1:
TABLE 1
As can be seen from the data in Table 1, the medical soft tissue adhesive provided in examples 1 to 8 has a viscosity of 550 to 750cp, a lap-shear tensile strength of 0.05 to 0.09MPa, a vascular adhesion time of 25 to 50s, a flow time of 7 to 8s, and a vascular adhesion film forming effect of A or B grade.
As can be seen from the data of comparative examples 1 and 1 to 2, the lap-shear tensile strength of the adhesive obtained without addition of retarder or without addition of polymerization inhibitor was reduced, and the vascular adhesion film-forming effect was deteriorated.
As can be seen from comparing the data of example 1 with the data of comparative examples 3 to 4, the addition of the polymerization inhibitor or retarder is too high, which results in a significant decrease in the lap-shear tensile strength of the adhesive, and the shorter flow time, the vascular adhesion film-forming effect is shown to be uncured.
Finally, comparing the data of example 1 with the data of examples 7 to 8, it was also found that the ratio of the amounts of retarder and polymerization inhibitor, which is not within the preferred range defined in the present invention, also affected the adhesion effect of the finally obtained adhesive to blood vessels.
The applicant states that the present invention is described by way of the above examples as a medical soft tissue adhesive, and a method of preparing and using the same, but the present invention is not limited to the above examples, i.e. it is not meant that the present invention must be practiced in dependence upon the above examples. It should be apparent to those skilled in the art that any modification of the present invention, equivalent substitution of raw materials for the product of the present invention, addition of auxiliary components, selection of specific modes, etc., falls within the scope of the present invention and the scope of disclosure.
Claims (10)
1. The medical soft tissue adhesive is characterized by comprising the following components in parts by weight:
2. the medical soft tissue adhesive of claim 1, wherein the α -cyanoacrylate comprises α -n-butyl cyanoacrylate and/or α -n-octyl cyanoacrylate.
3. The medical soft tissue adhesive according to claim 1 or 2, wherein the plasticizer comprises triethyl citrate and/or tributyl citrate.
4. A medical soft tissue adhesive according to any one of claims 1 to 3, wherein the thickening agent comprises cellulose acetate butyrate.
5. The medical soft tissue adhesive of any one of claims 1-4, wherein the retarder comprises any one or a combination of at least two of rosin, salicylic acid, or phosphoric acid;
preferably, the polymerization inhibitor comprises any one or a combination of at least two of hydroquinone, benzoquinone or sulfur dioxide, and more preferably, the combination of hydroquinone and sulfur dioxide.
6. The medical soft tissue adhesive according to any one of claims 1 to 5, wherein the mass ratio of the retarder to the polymerization inhibitor is (2 to 4): 1.
7. A method of preparing a medical soft tissue adhesive according to any one of claims 1 to 6, comprising: mixing alpha-cyanoacrylate, plasticizer, thickener, retarder and polymerization inhibitor to obtain the medical soft tissue adhesive.
8. The preparation method according to claim 7, characterized in that it comprises in particular: mixing a retarder, a solid polymerization inhibitor and a plasticizer, adding a thickener, and finally adding a gaseous polymerization inhibitor and alpha-cyanoacrylate for mixing to obtain the medical soft tissue adhesive.
9. The method according to claim 8, wherein the mixing time for mixing the retarder with the solid polymerization inhibitor and the plasticizer is 5 to 30 minutes;
preferably, the mixing time for mixing the gaseous polymerization inhibitor and the alpha-cyanoacrylate is 1 to 48 hours.
10. Use of a medical soft tissue adhesive vena cava adhesive according to any one of claims 1 to 7.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211579489.3A CN115715822A (en) | 2022-12-06 | 2022-12-06 | Medical soft tissue adhesive and preparation method and application thereof |
| CN2022115794893 | 2022-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117503985A true CN117503985A (en) | 2024-02-06 |
Family
ID=85257619
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211579489.3A Pending CN115715822A (en) | 2022-12-06 | 2022-12-06 | Medical soft tissue adhesive and preparation method and application thereof |
| CN202311521057.1A Pending CN117503985A (en) | 2022-12-06 | 2023-11-15 | Medical soft tissue adhesive and preparation method and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211579489.3A Pending CN115715822A (en) | 2022-12-06 | 2022-12-06 | Medical soft tissue adhesive and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN115715822A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117298328B (en) * | 2023-11-30 | 2024-03-08 | 四川国屹医疗科技有限公司 | Medical adhesive |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113679876B (en) * | 2021-08-13 | 2022-08-12 | 上海恩盛医疗科技有限公司 | Medical soft tissue adhesive and preparation method thereof |
| CN114796590A (en) * | 2022-04-26 | 2022-07-29 | 上海栗亮医疗科技有限公司 | Self-tackifying cyanoacrylate medical adhesive and preparation method thereof |
| CN114796591A (en) * | 2022-06-06 | 2022-07-29 | 北京康派特医疗器械有限公司 | Cyanoacrylate medical adhesive and preparation method and application thereof |
-
2022
- 2022-12-06 CN CN202211579489.3A patent/CN115715822A/en active Pending
-
2023
- 2023-11-15 CN CN202311521057.1A patent/CN117503985A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115715822A (en) | 2023-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117503985A (en) | Medical soft tissue adhesive and preparation method and application thereof | |
| US3221745A (en) | Method of bonding body tissue together using methylenemalonic acid esters | |
| US4035334A (en) | Medical adhesive | |
| CN115054723B (en) | Flexible adhesive | |
| CN104958781A (en) | Chemical medical adhesive composition and preparation method thereof | |
| EP2064300A2 (en) | Tissue adhesive compositions and methods thereof | |
| CN113827765A (en) | Implanted cyanoacrylate medical adhesive and application thereof | |
| CN105056285B (en) | It is a kind of can adhesion organization crack growth factor combine dressing and preparation method thereof | |
| CN113861451A (en) | Preparation method of biomedical tissue adhesive | |
| DE102005007920A1 (en) | Flexible adhesive composition, useful for closing wounds, particularly in surgery, comprises a polysaccharide and a cyanoacrylate | |
| CN104888268B (en) | Cyanoacrylate adhesive and its manufacture method | |
| RU2468824C1 (en) | Biological adhesive and method for preparing it | |
| CN110420347A (en) | A kind of adhesive of medical and preparation method thereof | |
| Kaplan et al. | In vitro toxicity test of ethyl 2-cyanoacrylate, a tissue adhesive used in cardiovascular surgery, by fibroblast cell culture method | |
| CN113398322B (en) | Medical adhesive material for vascular closure and preparation method thereof | |
| CN114796590A (en) | Self-tackifying cyanoacrylate medical adhesive and preparation method thereof | |
| CN111265720A (en) | Adipose tissue material rich in stem cells and preparation method thereof | |
| CN113350565B (en) | Medical adhesive material for vessel closure and preparation method thereof | |
| CN117298328B (en) | Medical adhesive | |
| WO2015014540A1 (en) | Improved cyanoacrylate compositions | |
| KR102281358B1 (en) | Medical silicone gel composition and preparation method | |
| RU2558089C1 (en) | Method for pre-implantation preparation of biological prostheses for cardiovascular surgery | |
| CN115845122B (en) | Photosensitive and temperature-sensitive mixed high-strength hydrogel | |
| EP2223706A2 (en) | Medical adhesive compound | |
| CN110038150B (en) | Preparation method of urushiol modified hemostatic gauze and urushiol modified hemostatic gauze |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |